Thermo Fisher Aims to Break Cell Therapy's Manufacturing Barrier

WALTHAM, Mass. – May 04, 2026 – Thermo Fisher Scientific today unveiled a new technology aimed at solving one of the most significant challenges in modern medicine: the complex and costly manufacturing of cell therapies. The introduction of the Gibco™ CTS™ DynaXS™ Single Use Bioreactor marks a critical step in the industry's push to scale up production of these life-changing treatments, moving them from niche applications to mainstream medical care.

The purpose-built platform is designed to help developers transition from small-scale laboratory methods to large-scale, automated, and regulatory-compliant manufacturing, a hurdle that has long constrained the growth and accessibility of therapies for cancer and other devastating diseases.

The High Cost of a Cure

For years, the promise of cell therapy—harnessing the body's own cells to fight disease—has been tempered by the immense practical difficulties of producing these treatments. The process is notoriously complex, particularly for autologous therapies like CAR-T, where a patient's cells are extracted, engineered in a lab, and then reinfused. Each patient represents a unique manufacturing batch, a "vein-to-vein" journey that is labor-intensive, logistically challenging, and astronomically expensive, with costs often running into the hundreds of thousands of dollars per dose.

This "scale-out" rather than "scale-up" model has created a significant bottleneck. Industry reports have consistently identified manufacturing as a primary driver of high therapeutic costs, limiting patient access and straining healthcare systems. Furthermore, the reliance on manual, open processes introduces variability and a higher risk of contamination, attracting intense scrutiny from regulatory bodies like the FDA and EMA. These agencies require strict adherence to Current Good Manufacturing Practice (cGMP) standards, and manufacturing robustness has been a frequent cause of delays and clinical holds for promising therapies.

As the cell therapy pipeline expands beyond oncology into autoimmune disorders and other chronic conditions, the pressure to solve these manufacturing issues has become acute. The industry urgently needs standardized, automated, and closed systems that can produce consistent, high-quality cells at a scale and cost that makes them a viable option for a broader patient population.

A Purpose-Built Platform for a New Era

Thermo Fisher's CTS DynaXS Single Use Bioreactor is engineered specifically to address these deep-rooted challenges. Unlike general-purpose bioreactors that may be adapted for cell therapy, the DynaXS is a "purpose-built" stirred-tank system designed from the ground up for the delicate task of expanding therapeutic cells. Its single-use design mitigates the risk of cross-contamination and eliminates the need for costly and time-consuming cleaning and validation between batches, a critical advantage in a multi-product facility.

The system is designed to be scalable, allowing therapy developers to use the same platform for small process development batches in the lab and then seamlessly transition to larger volumes required for clinical trials and commercial cGMP production. This consistency is crucial for simplifying the path to regulatory approval.

“Cell therapy manufacturers are navigating a rapidly expanding pipeline and increasing regulatory expectations,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business, in the company's announcement. “The CTS DynaXS bioreactor reflects our commitment to help deliver end-to-end, integrated solutions that enable customers to simplify scale-up, strengthen process control, and support the development of therapies intended for patient use.”

The Advantage of an Integrated Ecosystem

Perhaps the most significant strategic element of the DynaXS launch is its position within Thermo Fisher’s broader Cell Therapy Systems (CTS) portfolio. The company is not just selling a piece of hardware; it is offering a key component in a fully integrated, end-to-end manufacturing workflow. This ecosystem approach supports developers from the initial stages of cell isolation and activation through expansion, all the way to downstream processing.

For manufacturers, this integration offers substantial benefits. It simplifies procurement, streamlines workflows, and ensures that different components are designed to work together seamlessly. This can dramatically reduce the time and resources spent on validating a manufacturing process. It also provides a single point of contact for technical support and regulatory documentation, a crucial advantage when navigating the complex compliance landscape.

“Manufacturers want platforms that grow with them,” noted Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “With CTS DynaXS, we are providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey.”

This strategy places Thermo Fisher in a strong competitive position against other major players in the bioprocessing space, such as Sartorius with its Biostat STR® family and Cytiva with its Xcellerex™ systems. While competitors also offer robust and scalable bioreactors, Thermo Fisher is betting that the appeal of a unified, pre-qualified ecosystem will be a powerful differentiator for developers looking to de-risk their path to commercialization.

Unlocking Therapies Beyond Oncology

The impact of manufacturing innovation extends far beyond operational efficiency. By enabling more scalable and cost-effective production, technologies like the CTS DynaXS are critical for unlocking the full potential of cell therapy itself. While cancer has been the primary focus, researchers are actively exploring cell-based treatments for a vast range of conditions, including multiple sclerosis, lupus, rheumatoid arthritis, and other autoimmune diseases.

These emerging applications will require even greater production volumes and cost efficiencies to be viable. The ability to reliably manufacture high-quality cells at a lower cost of goods is the key that could open the door to treating hundreds of thousands, if not millions, of new patients. The DynaXS bioreactor and similar innovations are therefore not just engineering solutions; they are foundational technologies that could help democratize access to some of the most advanced medicines ever developed.

With over two decades of investment in the cell therapy space, Thermo Fisher's latest launch signals a deep and continued commitment to breaking down the barriers that stand between scientific discovery and patient impact. By tackling the critical manufacturing bottleneck head-on, the company is helping to build the infrastructure needed for the next generation of medicine.